DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

11/12/24 8:23:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $DMAC alert in real time by email

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company's management will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19, 2024 in New York City, New York. Management will be available for one-on-one meetings throughout the day.

Investors and attendees that would like to schedule a meeting with DiaMedica's management can contact their Craig-Hallum representative to arrange a meeting.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company's website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241112148074/en/

Get the next $DMAC alert in real time by email

Date	Price Target	Rating	Analyst
10/7/2024	$7.00	Buy	H.C. Wainwright
4/24/2024	$8.00	Buy	Craig Hallum
6/22/2023	$7.00	Perform → Outperform	Oppenheimer
6/30/2021	$38.00 → $32.00	Buy	Roth Capital

DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

Chat with this insight

Recent Analyst Ratings for $DMAC

$DMAC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on DiaMedica Therapeutics with a new price target

Craig Hallum resumed coverage on DiaMedica Therapeutics with a new price target

DiaMedica Therapeutics upgraded by Oppenheimer with a new price target

$DMAC Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Von Koch Thomas bought $3,000,000 worth of shares (1,200,000 units at $2.50) (SEC Form 4)

Large owner Stahlberg Jan bought $3,000,000 worth of shares (1,200,000 units at $2.50) (SEC Form 4)

Wambeke David J. bought $49,200 worth of Voting Common Shares (20,000 units at $2.46), increasing direct ownership by 4% to 527,114 units (SEC Form 4)

$DMAC Press Releases

Fastest customizable press release news feed in the world

$DMAC Large Ownership Changes

This live feed shows all institutional transactions in real time.

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia